An Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of Rivaroxaban in Subjects With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Cardiovascular disorders; Renal failure
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 18 May 2015 Status changed from recruiting to completed, according to to ClinicalTrials.gov record.
- 17 Feb 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 20 Nov 2014 New trial record